EN DE
Watch Dong-A St for free: once a week we email you where price and fair value stand.
Data-driven stock valuation

Dong-A St (170900) fair value: what the stock is really worth

As of Nov 19, 2026: fair value (intrinsic value) of Dong-A St stock KRW 10,616, price KRW 34,000, that is 68.8% below the price, quality 37 out of 100. Rating: strongly overvalued. Calculated from audited financials with 2 of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare KR · ISIN KR7170900005

DA Dong-A St logo Some data Nov 18, 2026

Dong-A St

170900 · KO

Far too expensive (fair value 69% below the price), weak company and falling price: meets none of the 3 rules.

Follow free in the weekly email
Low debt 
Revenue last quarter +16% vs. a year ago. 
Expensive Growth (revenue 5y +6.6 %/yr in KRW) 
Thin margins · 1.0% net margin (TTM) 
2.1% dividend yield · Watch coverage
Some data 
Fair value 10,616 KRW · Strongly overvalued 
Quality 37/100 
Falling price (downtrend) 
Negative free cash flow 
Trails peers (5/13) 
Narrow moat 21/100
Watch Dong-A St for free: once a week we email you where price and fair value stand. Watch for free

What runs behind every stock

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

83,714 KRW 32,000 KRW Fair Value 10,616 KRW Jun 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 18, 2026.

How to read this chart

60‑month range 32,000 KRW – 83,714 KRW · fair‑value band 10,616 KRW – 22,764 KRW · the 34,000 KRW price screens above the 10,616 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 18, 2026.

Follow Dong-A St in your weekly email

Every Wednesday you see whether Dong-A St is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Dong-A ST Co., Ltd. develops, manufactures, and markets pharmaceutical products in South Korea and internationally.

Show moreShow less

It offers various ethical drugs, including Clofazimine cap. for lepromatous leprosy; Closerin Cap for active pulmonary and extra-pulmonary tuberculosis; Eporon inj./PFS for anemia associated with chronic renal failure; Gemcit inj. to treat non-small cell lung, pancreatic, breast, bladder, and ovarian cancers; Gonadopin inj./PFS for ovarian hyperstimulation and anovulation; Growtropin II Inj./AQ /cartridge to treat growth failure due to an inadequate secretion of growth hormone and idiopathic short stature, small for gestational age, turner syndrome; Leucostim Inj. for neutropenia in patients receiving myelosuppressive chemotherapy; Mainta inj. for non-small cell lung cancer and malignant pleural mesothelioma; Monotaxel inj. to treat breast, non-small cell lung, prostate, head, and neck cancers, as well as gastric adenocarcinoma; Motilitone tab. for use in functional dyspepsia treatment; Stillen tab/ Stillen 2X tab. to treat gastritis; Suganon tab./Sugamet XR tab. and Sugadapa tab./Sugatree XR tab for type 2 diabetes mellitus; DA-3880 PFS to treat renal anemia and darbepoetin-alfa; and Zydena tab. for erectile dysfunction treatment.

The company also provides licensed-in and licensed-out drugs; and medical devices, which cover high-technology medical devices, custom-made products, and sets of artificial cardiac circuits for use in open-heart surgery.

Dong-A ST Co., Ltd. was founded in 1932 and is headquartered in Seoul, South Korea.

Stock analysis

Dong-A St (170900) currently trades at 34,000 KRW, while our model-based Fair Value estimate is 10,616 KRW, 69% below the price, so the stock looks overvalued today.

Show more

Valuation

How firm this estimate is: it rests on 2 models at a data quality of 91/100, which puts the data coverage at medium.

Scenario range: 10,616 KRW (bear) to 22,764 KRW (bull), the price of 34,000 KRW sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 37/100 (below-average quality), in the Healthcare sector.

Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.

Dong-A St reported revenue of 809B KRW in FY2025 versus 593B KRW in FY2021, a compound +8.1%/yr. Reported net income was −28.6B KRW in FY2025.

Key figures

Market cap 327B KRW (≈ $246M) Micro · P/E ratio 37.6 · P/S ratio 0.38 · EPS (TTM) 901.60 KRW · Dividend yield 2.1% · Net margin 1.0% · Return on equity 0.9% · Return on assets (EBIT) 0.4% (5-year average).

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 21 out of 100 (medium confidence).

What moves the price

The share trades about 37% below its 52-week high and 6% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −27% fair-value upside, at −69%, 170900 screens richer than that median.

Fair Value models

Bear 10,616 KRW Fair Value 10,616 KRW Bull 22,764 KRW
Price 34,000 KRW · Downside -68.8%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 11 months old). Earnings retained since then (178.40 KRW per share) are deliberately not added. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
EV/EBITDA n/a 10,616 KRW 22,764 KRW 62
NCAV (Graham) 25,816 KRW 34,593 KRW 51,632 KRW 54
All 2 models by family
Multiples
EV/EBITDA n/a 10,616 KRW 22,764 KRW 62
Asset-Based
NCAV (Graham) 25,816 KRW 34,593 KRW 51,632 KRW 54

Open the full fair value analysis →

Quality Score breakdown

Overall quality 37/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 20
How much profit the company makes from its sales and capital
Quality Growth 44
Are margins and returns getting better?
Cashflow 13
Do the profits arrive as real cash?
Financial strength 33
Debt, balance sheet and risk of trouble
Investment 84
Does it invest with discipline instead of growing at any price?
Low Volatility 79
How calm the share price moves, does not count
Price momentum 19
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 5
Distance to the 52-week high, does not count
New shares 49
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 41/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+15.9%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+8.4%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+6.6%
Start year 2020 (pandemic). Over 10 years: +3.6% a year
Revenue growth 12 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+4.1%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
5.8% (2020) → 0.1% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

170900 screens overvalued: fair value 69% below the price. Compare with Merck KGaA →

Compare Dong-A St with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 608 stocks

Beats the industry median on 5/13 measures
Overall it trails its industry peers.
Valuation
Quality Score 37 · Bottom 25%
Fair Value upside −68.8% · Bottom 25%
Profitability
Return on equity (12 months) 0.9% · Below median
Return on assets −2.0% · Below median
Net margin (12 months) 1.0% · Below median
Operating margin (12 months) 2.8% · Below median
Growth and dividend
Revenue growth (quarter YoY) 15.8% · Above median
Dividend yield (12 months) 2.1% · Above median
Balance sheet
Debt / equity 0.47× · Highest 25%

Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper

P/E (12 months) 37.6× · Pricier than median
P/B 0.51× · Cheapest 25%
P/S (12 months) 0.38× · Cheapest 25%
EV/EBITDA 8.2× · Cheaper than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 20
FUTURE (revenue growth)79 · sector 29
PAST (return on equity)3 · sector 26
HEALTH (low debt)77 · sector 96
DIVIDEND (yield)41 · sector 33

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Zoetis Inc ZTS $85.57 $113.53 +33% vs 170900
Jiangsu Hengrui Pharmaceuticals Co 600276 ¥46.88 ¥52.43 +12% vs 170900
Sun Pharmaceutical Industries Limited SUNPHARMA ₹1,900 ₹1,983 +4% vs 170900
Haleon plc HLN $9.08 $8.47 −7% vs 170900
Merck KGaA MRK €148.40 €108.83 −27% vs 170900
Galderma Group GALD CHF 184.70 CHF 112.46 −39% vs 170900
Takeda Pharmaceutical Company TAK $21.27 $11.23 −47% vs 170900
Sandoz Group SDZ CHF 81.24 CHF 41.06 −49% vs 170900
Teva Pharmaceutical Industries Limited TEVA $42.23 $20.74 −51% vs 170900
Divi's Laboratories Limited DIVISLAB ₹11,178 ₹1,567 −86% vs 170900

Explore undervalued stocks

More undervalued Healthcare stocks →

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Dong-A St: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Dong-A St Fair Value". https://www.fairvalue-calculator.com/stock/170900

Frequently asked questions

Is Dong-A St (170900) overvalued or undervalued?
As of Nov 18, 2026, our model estimates a fair value of 10,616 KRW versus a price of 34,000 KRW, about 69% lower (overvalued).
What is the fair value of 170900?
Our model-based fair value for Dong-A St is 10,616 KRW (as of Nov 18, 2026), built from audited fundamentals. The current price: 34,000 KRW.
What is the quality score of 170900?
Dong-A St has a Quality Score of 37/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Dong-A St (170900)?
We do not set a price target; the yardstick is the fair value of 10,616 KRW (as of Nov 18, 2026) from 2 valuation models. Cautious scenario 10,616 KRW, optimistic scenario 22,764 KRW. It is a calculation from audited fundamentals, not an analyst target.
What is the Dong-A St stock forecast for 2026?
Our models put fair value at 10,616 KRW, about 69% lower versus a price of 34,000 KRW (overvalued). Cautious scenario 10,616 KRW, optimistic scenario 22,764 KRW. The calculation is refreshed regularly with new filings.
What is the revenue of Dong-A St (170900)?
Dong-A St reported trailing-twelve-month revenue of about 861B KRW (latest available figure, as of Nov 18, 2026).
Does Dong-A St pay a dividend?
Dong-A St currently shows a dividend yield of 2.06% relative to its recent price (as of Nov 18, 2026).
How much is the dividend of Dong-A St (170900) and when is the ex-dividend date?
Dong-A St pays a dividend of 700.00 KRW per share a year, a dividend yield of 2.1%. The last ex-dividend date was Mar 10, 2026. The payout ratio is 77.6% of earnings. Our assessment: Watch coverage. The dividend isn’t fully covered by free cash flow or earnings, part of it is funded from reserves or debt. Fine for now, but worth watching: if it stays uncovered, the dividend could be cut.
What is the intrinsic value of Dong-A St (170900)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Dong-A St it is 10,616 KRW per share (as of Nov 18, 2026), against a price of 34,000 KRW. It is the blended result of 2 valuation models in 2 families (Multiples, Asset-Based).
Is Dong-A St stock overvalued or undervalued in 2026?
As of Nov 18, 2026, 170900 trades above its calculated fair value: price 34,000 KRW, fair value 10,616 KRW, a gap of about −69% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 170900?
No. The price is what the market pays today (34,000 KRW); the fair value is what the company's own numbers justify (10,616 KRW). For Dong-A St the two are 23,384 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is Dong-A St worth?
The market values Dong-A St at about 327B KRW (market capitalisation, as of Nov 18, 2026). Per share that is 34,000 KRW; our models calculate a fair value of 10,616 KRW per share.
What do the bullish and bearish scenarios say about 170900?
Our models span a range for Dong-A St: cautious scenario 10,616 KRW, base 10,616 KRW, optimistic 22,764 KRW per share (as of Nov 18, 2026, price 34,000 KRW). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 170900?
Dong-A St trades at a price-to-earnings ratio of 37.6 (as of Nov 18, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of 10,616 KRW is built from several models across several years. Other multiples: P/B 0.5, P/S 0.4, EV/EBITDA 8.2.
How solid is the balance sheet of Dong-A St (170900)?
Balance-sheet figures for Dong-A St (as of Nov 18, 2026): return on equity 0.9%, debt of 0.47 per unit of equity. They feed the Quality Score of 37/100, which measures business quality independently of the share price.
How far is 170900 from its 52-week high?
Dong-A St trades at 34,000 KRW, about 37% below its 52-week high of 54,197 KRW and 6% above the low of 32,000 KRW (as of Nov 19, 2026). Distance from the high says nothing about value: that is what the fair value of 10,616 KRW is for.
Which stocks are comparable to Dong-A St?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Galderma Group, Teva Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Dong-A St stock attractive at the current price?
The data as of Nov 18, 2026: price 34,000 KRW, calculated fair value 10,616 KRW (−69%), Quality Score 37/100, from 2 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 170900 calculated?
We run Dong-A St through 2 models from 2 families: Multiples, Asset-Based. Every model gets the same audited fundamentals; the fair value of 10,616 KRW builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 12.0% above its aggregate fair value. Dong-A St itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Dong-A St (170900)?
The closing price on Nov 19, 2026 was 34,000 KRW. Our model-based fair value is 10,616 KRW, about 69% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Dong-A St right now?
The price sits above even our optimistic bull case (22,764 KRW). The favourable scenario is already priced in. Weak quality (37/100) and above fair value at the same time, the margin of safety is missing on both counts. A fairly wide model range (10,616 KRW to 22,764 KRW) leaves room in how you read the outcome.

Key figures of Dong-A St

How large is the market capitalisation of Dong-A St (170900)?
The market capitalisation of Dong-A St is 327B KRW (≈ $246M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Dong-A St (170900)?
The price-to-sales ratio of Dong-A St is 0.38 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Dong-A St (170900)?
Earnings per share at Dong-A St are 901.60 KRW (price ÷ EPS = P/E 37.6). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Dong-A St (170900)?
The dividend yield of Dong-A St is 2.1% (payout 77.6%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Dong-A St (170900)?
The net margin of Dong-A St is 1.0% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Dong-A St (170900)?
The return on equity (ROE) of Dong-A St is 0.9% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Dong-A St (170900)?
On an EBIT basis the return on assets of Dong-A St is 0.4% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Dong-A St (170900)?
The operating margin of Dong-A St is 2.8% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Dong-A St (170900)?
Revenue at Dong-A St is growing 15.8% versus a year earlier (3y avg +8.4%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Dong-A St (170900)?
Earnings per share at Dong-A St are down 64.2% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Dong-A St (170900) generate?
The free cash flow of Dong-A St is −7.8B KRW (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Dong-A St (170900) carry?
The net debt of Dong-A St is 366B KRW (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Dong-A St in the live analysis

One click puts Dong-A St on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.